Legchenko et al. found that the PPAR-γ agonist pioglitazone reversed pulmonary hypertension through fatty acid oxidation mainly associated with lipid metabolism and disturbed mitochondrial morphology/function in right ventricular failure and pulmonary vascular hypertension49. The gene discussed is PPARG; the disease is pulmonary hypertension.